Boolean Genetic Circuits for Tumor-Selective Bacterial Therapeutics

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing tumor-targeted bacteria for cancer therapy face challenges in effectively colonizing tumors and expressing therapeutic agents, leading to insufficient antitumor activity, despite successful targeting, due to limitations in toxin secretion, surface display, and specificity for tumor tissue.

Innovation Solution

Genetically engineered bacteria with modified toxins, chimeric toxins, and improved secretion systems, along with immunotherapeutic agents, are designed to enhance tumor colonization and specificity, utilizing Boolean control pathways for targeted expression of therapeutic proteins.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional toxin secretion systems are used in tumor-targeted bacteria, then the bacteria can be engineered to express therapeutic agents, but the toxin secretion efficiency is insufficient leading to weak antitumor activity

Engineering Contradiction:

Improveantitumor activityVSAvoidtoxin secretion efficiency

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent modifies toxin secretion parameters by engineering bacteria to express modified toxins with altered secretion properties. The modified toxins incorporate changes in their molecular structure and secretion signals to enhance secretion efficiency from bacterial cells, directly addressing the insufficient toxin secretion problem while maintaining tumor-targeting capability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite therapeutic systems by combining multiple components: tumor-targeting bacteria, modified toxins with enhanced secretion properties, and immunotherapeutic agents. This composite approach allows the system to overcome individual limitations by synergistic interaction between components, resulting in improved antitumor activity

Inventive Principle:

Principle #40Composite materials

2Productivity

If bacteria are engineered to express therapeutic proteins, then therapeutic efficacy can be enhanced, but specificity for tumor tissue is reduced leading to off-target effects in normal tissues

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidoff-target effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by making the bacteria's therapeutic protein expression conditional upon local tumor microenvironment conditions. The bacteria express therapeutic proteins only when specific Boolean conditions related to tumor physiology are met, ensuring localized action at the tumor site while sparing normal tissues from off-target effects

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent introduces tumor-specific conditions and modified toxin systems as intermediaries between the bacteria and normal tissues. These intermediaries act as selective filters that allow therapeutic action only in the tumor microenvironment, preventing direct harmful effects on healthy cells while maintaining high therapeutic efficacy

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If bacteria colonize tumors effectively, then therapeutic agent delivery is improved, but colonization capability is limited reducing overall antitumor impact

Engineering Contradiction:

Improvetherapeutic agent deliveryVSAvoidbacterial colonization

Core Design Contradiction:

ProductivityVSQuantity of substance

Solution Approach 1:

The patent applies preliminary action by pre-engineering bacteria with enhanced colonization properties before tumor administration. The bacteria are modified in advance to express factors that facilitate tumor penetration, survival in the tumor microenvironment, and sustained colonization, ensuring adequate bacterial presence for effective therapeutic agent delivery

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12537071B1Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Publication Date: 2026.01.27 BERMUDES DAVID GORDON

AI summary

Tumor-selective expression of therapeutic molecules by bacteria is achieved by one or more AND, NOR, OR, NOT and/or NAND gate genetic circuits. The therapeutic molecules can be proteins, metabolites or catabolites, and may also be immunotherapeutics or immunotherapeutic cytotoxins. Single or multiple expression components may be used. Tumor selective expression of multimeric proteins utilizes multimerization as to complete the genetic circuit. Genetic circuits that are unlinked, function to achieve a combined effect on specificity of delivery of antitumor therapeutic molecules. Compositions and methods to generate silica, PEG and Poly-HPMA coated bacteria are also provided. Compositions and methods for selectively sensing or imaging tumors are also described.